In addition, as previously seen in CRC [82,83], Xun et al. confirmed that JMJD3 is activated by vitamin D analogues such as paricalcitol (vitamin D receptor agonist), also resulting in decreased stem-cell-like properties [89]. This evidence concerns the gene KDM6B and colorectal carcinoma.